# Protuoso Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/protuoso-bio

- Industry: Biotechnology
- Headquarters: San Carlos, US
- Website: www.protuoso.bio/
- Total disclosed funding: $9.5M
- Latest round: Seed (May 27, 2026)
- Investors on record: 4

## About

Based in the US, Protuoso Bio specializes in developing MUXBODIES™, advanced multifunctional protein architectures aimed at addressing complex diseases through innovative protein engineering and synthetic biology.Protuoso Bio is engaged in the development of sophisticated protein architectures to tackle complex diseases. The company is headquartered in San Carlos, US. In May 2026, Protuoso Bio raised USD 9.5 mn in Seed funding co-led by Taya Venture Capital and Darwin Ventures along with NSG Ventures, SEEDS, and others. This funding round represents the total amount raised by the company. The founder of Protuoso Bio has not been specified, but the company is focused on advancing its unique technologies.Protuoso Biosciences primarily focuses on the development of MUXBODIES™, which are sophisticated multifunctional protein architectures engineered through advanced AI-driven protein engineering and synthetic biology. These products are designed to address complex diseases that currently lack effective therapeutic options, integrating precision design with scalable innovation to enhance efficacy and safety. The MUXBODIES™ are part of a broader therapeutic portfolio targeting areas such as advanced cardiometabolic disease and armored immune cell engagement. The company’s innovative hub-and-spoke model enables it to efficiently develop multiple therapeutic assets simultaneously, allowing for parallel innovation and effective resource allocation. Protuoso’s products are positioned for markets in North America, Europe, and Asia, targeting pharmaceutical companies, healthcare providers, and research institutions that require biologics for complex patient needs.Protuoso Biosciences engages in revenue generation through partnerships and collaborations with pharmaceutical companies, research institutions, and healthcare organizations. The company’s business transactions revolve around the licensing of its proprietary MUXBODIES™ technology and collaborative agreements for product development. These partnerships may involve upfront payments, milestone-based payments tied to development progress, and royalties on future sales of developed therapeutics. The transactional framework emphasizes value-sharing based on the therapeutic efficacy and market potential of the MUXBODIES™, creating a diversified revenue stream anchored in its innovative platform. 
In May 2026, Protuoso Bio raised USD 9.5 million in seed funding co-led by Darwin Ventures and Taya Venture Capital, with participation from NSG Ventures and SEEDS Capital. The company plans to utilize the May 2026 funding to advance its multifunctional protein engineering platform and pipeline across cardiometabolic, oncology, and autoimmune diseases.

## Funding rounds

- Seed, May 27, 2026, $9.5M — Darwin Ventures, SEEDS Capital, Taya Venture Capital, NSG Ventures

## Investors

- Darwin Ventures (https://capitalatlas.ai/funds/darwin-ventures) — Seed
- SEEDS Capital (https://capitalatlas.ai/funds/seeds-capital) — Seed
- Taya Venture Capital (https://capitalatlas.ai/funds/taya-venture-capital) — Seed
- NSG Ventures (https://capitalatlas.ai/funds/nsg-ventures) — Seed